论文部分内容阅读
目的探讨利用奥扎格雷钠联合黛力新对脑梗死患者抑郁、焦虑的病情的治愈效果以及预后的影响。方法将我院2013年4月至2014年8月期间收诊的90例脑梗死患者随机分成实验组和对照组。对照组给予奥扎格雷钠治疗,实验组给予奥扎格雷钠+黛力新治疗,3个月后观察两组在治疗前后的焦虑抑郁症状改善情况、日常生活能力、神经功能及预后效果。结果治疗前,两组患者焦虑自评量表(SAS)评分和抑郁自评量表(SDS)评分无显著差异(P>0.05),治疗3个月后,实验组SAS评分和SDS评分以及日常生活能力(MBI)、神经功能(CNS)评分均显著低于对照组(P<0.01);实验组和对照组的总有效率分别为91.11%、73.33%,差异有统计学意义(P<0.01)。结论奥扎格雷钠联合黛力新对脑梗死患者的焦虑和抑郁等负面情绪有良好的治疗效果,具有积极的临床意义。
Objective To investigate the effect of ozagrel combined with Deanin on the curative effect and prognosis of depression and anxiety in patients with cerebral infarction. Methods Ninety patients with cerebral infarction admitted from April 2013 to August 2014 in our hospital were randomly divided into experimental group and control group. The patients in the control group were treated with ozagrel sodium. The patients in the experimental group were treated with ozagrel sodium and dexamethasone for 3 months. The improvement of anxiety and depressive symptoms, daily living ability, neurological function and prognosis were observed in both groups before and after treatment. Results Before treatment, SAS scores and SDS scores of two groups had no significant difference (P> 0.05). After three months of treatment, SAS scores and SDS scores of the experimental group and daily (P <0.01). The total effective rates of experimental group and control group were 91.11% and 73.33%, respectively, with significant difference (P <0.01) ). Conclusions Ozagrel combined with Deanxit has good therapeutic effect on negative emotions such as anxiety and depression in patients with cerebral infarction, which has a positive clinical significance.